Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000800011 | SCV000939708 | likely benign | Congenital myasthenic syndrome 4A | 2023-12-29 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002534625 | SCV003722197 | uncertain significance | Inborn genetic diseases | 2022-11-21 | criteria provided, single submitter | clinical testing | The c.1169G>C (p.R390P) alteration is located in exon 10 (coding exon 10) of the CHRNE gene. This alteration results from a G to C substitution at nucleotide position 1169, causing the arginine (R) at amino acid position 390 to be replaced by a proline (P). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Gene |
RCV004783861 | SCV005396930 | uncertain significance | not provided | 2024-05-09 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Natera, |
RCV001274711 | SCV001459091 | uncertain significance | Congenital myasthenic syndrome | 2020-01-24 | no assertion criteria provided | clinical testing |